European Society for Medical Oncology (ESMO)

The European Society for Medical Oncology (ESMO) is the leading professional organisation for medical oncology. With more than 25,000 members representing oncology professionals from over 150 countries worldwide, ESMO was founded in 1975.

Long-Term Follow-Up Results of MPDL3280A in Metastatic Renal-Cell Carcinoma

ESMO 2014 – Immuno-Oncology

Anti–PD-L1 Monoclonal Antibody MPDL3280A in Metastatic Urothelial Bladder Cancer

ESMO 2014 – Immuno-Oncology

Updated OS Data for the CA184-043 Trial: Immunotherapy with Ipilimumab Does Not Improve Survival in Patients with Metastatic Prostate Cancer

ESMO 2014 – Immuno-Oncology

Two Dosing Schedules of Pembrolizumab for Patients with Advanced Melanoma

ESMO 2014 – Immuno-Oncology

Nivolumab Improves Survival in Ipilimumab-Naïve Patients with Advanced Melanoma

ESMO 2014 – Immuno-Oncology

Nivolumab versus Investigator’s Choice of Chemotherapy in Patients with Advanced Melanoma

ESMO 2014 – Immuno-Oncology

Interim Analysis of BATON-CRC: Tivozanib plus mFOLFOX6 in Patients with Metastatic Colorectal Cancer

ESMO 2014 – Gastrointestinal and Head & Neck Cancer

Cetuximab, Fluorouracil, and Cisplatin, with/without Docetaxel, in Recurrent or Metastatic Head and Neck Cancer

ESMO 2014 – Gastrointestinal and Head & Neck Cancer

Pembrolizumab in HPV-Positive Head and Neck Cancer

ESMO 2014 – Gastrointestinal and Head & Neck Cancer

Association of HPV and p16 Status with Cetuximab plus Radiotherapy in Locally Advanced Head and Neck Cancer

ESMO 2014 – Gastrointestinal and Head & Neck Cancer

Page 9 of 9

1
2
3
4
5
6
7
8
9